How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

23 results for

Asp.Net Entity Framework

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Treatment of Multiple Myeloma

, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating (...) of Interest The Expert Panel was assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at ). All members of the Expert Panel completed ASCO’s disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include

2019 American Society of Clinical Oncology Guidelines

2. Appropriate care at the end of life

to our members the elements that favour the best care of the patients), Isabelle De Cartier d’Yves (Palliabru) Payments to speak, training remuneration, subsidised travel or payment for participation at a conference: Marie Friedel (For the second congres ICPCN, Fund Soeur Léontine) Presidency or accountable function within an institution, association, department or other entity on which the results of this report could have an impact: François De Vleesschouwer (Alzheimer Liga Vlaanderen vzw), Patrick (...) deMens. Recommendations/results of research passing to our local entities (Huizen van de Mens) and our member organization steering group Morele bijstand, which coordinates the free humanistic consultants in the healthcare sector), Johan Wens (President PHA (Palliatief hulpverlening Antwerpen vzw) Layout: Joyce Grijseels, Ine Verhulst Disclaimer: ? The external experts were consulted about a (preliminary) version of the scientific report. Their comments were discussed during meetings. They did not co

2018 Belgian Health Care Knowledge Centre

3. Improving the health of the public by 2040

if we are to capitalise on the digital revolution for health. It will also require us to collectively address issues associated with data access, ethics, trust, regulation and skills. We therefore call for ongoing efforts by research funders and key stakeholders to stimulate new research programmes and approaches, and to invest in the necessary transdisciplinary training, for the integration, manipulation and analysis of these data within appropriate ethical and regulatory frameworks. 3. Developing (...) (such as the Administrative Data Research Network, the Cabinet Office, NHS Digital, Involve, and the commercial sector) to maximise the potential of data generated within and outside the health system, within appropriate ethical and regulatory frameworks, for health of the public research. This should be linked to existing major health informatics investments such as the Farr Institute of Health Informatics Research. In particular, we recommend that key research funders support a programme of research to better

2017 Academy of Medical Sciences

4. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value

for Healthcare Research and Quality ASP Average sales price B-ALL B-cell acute lymphoblastic leukemia Allo-SCT Allogeneic stem cell transplant ASP Average sales price Auto-SCT Autologous stem cell transplant CAR-T Chimeric antigen receptor T-cell CNS Central nervous system CR Complete remission CRi Complete remission with incomplete hematologic recovery (leukemia) CRS Cytokine release syndrome CSF Cerebrospinal fluid DLCBL Diffuse large B-cell lymphoma ECOG Eastern Cooperative Oncology Group Performance (...) , neurotoxicity, B-cell aplasia), but they are manageable and perceived by clinicians as arguably no worse than the serious AEs associated with chemotherapy in this patient population. Thus, the estimated net health benefit is substantial. However, the level of certainty about the magnitude of the net health benefit compared to other therapies (clofarabine, blinatumomab, etc.) is low because there are no comparative trials and the existing single-arm trials are small with relatively short follow-up (8.7

2018 California Technology Assessment Forum

5. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

of infliximab, net pricing estimates for all reviewed drugs were derived from SSR Health, LLC, which combines data on unit sales with publicly-disclosed US sales figures that are net of discounts, rebates, concessions to wholesalers and distributors, and patient assistance programs to derive a net price. The derived net price is at the unit level and across all payer types. 43 Infliximab, which, because it is administered in-office or clinic, is priced based on Average Sales Price (ASP) plus a mark-up (...) Assessment Framework for 2017-2019, ICER will now include in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create headroom in health care budgets for higher-value innovative services (for more information, see https://icer-review.org/final-vaf-2017-2019/). ICER encourages all stakeholders to suggest services (including treatments and mechanisms of care) currently used for people with psoriasis that could be reduced, eliminated

2018 California Technology Assessment Forum

6. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value

admission for treatment administration included the per diem cost for hospital days and the costs of therapies administered during the hospitalization. Future bundled payments were assumed to approximate the cost of the resources used under a fee-for-service framework. The unit cost for each treatment is reported in Table ES12. The average sales price (ASP) for all treatments was used except for the two CAR-T therapies, where wholesale acquisition cost (WAC) was the only available estimate. A hospital (...) AIC Akaike information criterion AHRQ Agency for Healthcare Research and Quality B-ALL B-cell Acute lymphoblastic leukemia Allo-SCT Allogeneic stem cell transplant ASP Average sales price Auto-SCT Autologous stem cell transplant CAR-T Chimeric antigen receptor T-cell CNS Central nervous system CR Complete remission CRi Complete remission with incomplete hematologic recovery (leukemia) CRS Cytokine release syndrome CSF Cerebrospinal fluid DLCBL Diffuse large B-cell lymphoma ECOG Eastern Cooperative

2018 California Technology Assessment Forum

7. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

with publicly-disclosed US sales figures that are net of discounts, rebates, concessions to wholesalers and distributors, and patient assistance programs to derive a net price. The derived net price is at the unit level and across all payer types. 43 Infliximab, which, because it is administered in-office or clinic, is priced based on Average Sales Price (ASP) plus a mark-up of 9.5%. 44 We used drug-specific rebates, in contrast to our 2016 report that used drug class-based rebates, because rebates varied (...) therapy. Problems with coverage • Requirements for “step therapy” forcing patients to start treatment with less efficacious medications. • Lack of clarity in the exception process and timing for physicians and patients. • Patients have to “start over” with “step therapy” of previously-tried medications after switching insurance. • High out of pocket costs hindering treatment or leading to undertreatment. Potential Cost-Saving Measures in Psoriasis As described in its Final Value Assessment Framework

2018 California Technology Assessment Forum

8. Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value-Based Price Benchmarks

progress) will also be treated at the time of progression with the TKI osimertinib. 4,11 Second-line TKI therapy in such patients likely provides additional survival benefits; analysis of this type of treatment pathway was beyond the scope of our review. Comparative Clinical Effectiveness: Summary For patients with EFGR+ advanced NSCLC, we have high certainty that TKI therapy provides at least a small net health benefit (“B+”) relative to platinum chemotherapy. This reflects high certainty that first

2017 California Technology Assessment Forum

9. Key policies for addressing the social determinants of health and health inequities

was first conducted to identify policy themes. Targeted searches of policy frameworks and guidance from intergovernmental organizations and other international organizations were conducted to identify policy options within each policy theme that are likely to be relevant to the WHO European Region. Only documents published in English were included. Visual maps were developed to explore the relationships between the policy options and between themes. Results A wide range of policy options for addressing (...) ). Actions in this area are supported by the United Nations Educational, Scientific and Cultural Organization’s Moscow Framework for Action (23), which calls on governments to take greater responsibility and action across both government and society to protect children’s rights and 7 improve neonatal health, birth outcomes, nutrition and care. The Organisation for Economic Co-operation and Development (OECD) report series, Starting strong (24,25), outlines key components of strategies to develop

2017 WHO Health Evidence Network

10. Antiemetics

of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases (...) of or related to any use of this information, or for any errors or omissions. Guideline and Conflicts of Interest The Expert Panel was assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at ). All members of the Expert Panel completed ASCO’s disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory

Full Text available with Trip Pro

2017 American Society of Clinical Oncology Guidelines

12. Initial Diagnostic Workup of Acute Leukemia

received during the public comment period, and expert panel consensus. Results.—Twenty-seven guideline statements were estab- lished,whichrangedfromrecommendationsonwhatclinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing shouldbeperformedandhowtheresultsshouldbereported. Conclusions.—The guideline provides a framework (...) of mixed-phenotype acute leukemia (MPAL), and included provisional entities of AML that were based on gene mutation studies. Since 2008, many other mutations have been described in all types of AL, and epigenetic changes, including protein and microRNA (miRNA) ex- pression and global and gene-speci?c methylation, have been reported to be common and prognostically relevant in AL. 6,7 The 2016 WHO classi?cation 8 of AL continued to de?ne some disease entities by a combination of morpho- logic

2016 College of American Pathologists

13. Enhancing community accountability, empowerment and education outcomes in low and middle-income countries: A realist review

6.2 Using the theoretical model 131 7. Summary and Observations 137 8. Recommendations 139 8.1 Policy and practice 139 8.2 Evaluation and research 142 References 145 Appendices 156 Appendix 1.1: Authorship of this review 156 Appendix 1.2: End-User Group 157 Appendix 2: Initial rough theory (as outlined in study protocol) 158 Appendix 3: Detailed discussion of contextual features 171 1 List of abbreviations ASP Autonomous Schools Programme ACE Community Education Association ATEO Assistant Thana

2014 EPPI Centre

14. Costs and impacts on the economy and productivity due to mental ill health

In the earlier study the authors found that high psychological distress increases absenteeism by 1.7%, decreases employee performance at work by 6.1%, resulting in a net productivity loss of 6.7%. 9 In the latter study, Hilton et al. (2010) estimated that psychological distress produces an $5.9 billion reduction in Australian employee productivity per annum. 10 Schofield used a combination of data sources to populate a microsimulation model of health and disability. 11,12 The authors found that individuals (...) who had retired early due to depression had 73% lower income then their full-time employed counterparts. The national aggregate cost of this early retirement equated to $278 million in lost income taxation revenue, $407 million in additional transfer payments and around $1.7 billion in gross domestic product. 11 Laplagne et al. (2007) used data from Household, Income and Labour Dynamics in Australia (HILDA) to examine the effects of health and education within an integrated modelling framework

2013 Sax Institute Evidence Check

15. An Update of Comprehensive Evidence-Based Guidelines for Interventional Techniques in Chronic Spinal Pain - Part 1 - Introduction and General Considerations

outcomes, and provide ratings of both the quality of evidence and the strength of recommendations • Reconsidered and revised as appropriate when im- portant new evidence warrants modifications of recommendations. As a result, researchers, clinicians, professional or- ganizations, and governments in the United States and other countries are looking for a sensible approach to health care with practicable and replicable EBM and CER. Multiple frameworks have been developed to im- prove the ability (...) review of clinical practice guidelines including specifying mecha- nisms for ensuring public stakeholder comment; and el- ements essential to clinical practice guideline updating, including ongoing monitoring and review of the clini- cal guideline-relevant scientific literature and factors indicating the need for updates. Unlike many develop- ment methodologies, which are specific to a particular guideline development, entity, and clinical problem, the 8 standards described by the IOM provide

2013 American Society of Interventional Pain Physicians

16. Developing and Sustaining Nursing Leadership

GUIDELINES WWW.RNAO.ORG 2 Developing and Sustaining Nursing LeadershipDeveloping and Sustaining Nursing Leadership 3 BEST PRACTICE GUIDELINES WWW.RNAO.ORG Table of Contents Background to the Healthy Work Environments Best Practice Guidelines project 6 Organizing framework for the Healthy Work Environments Best Practice Guidelines project 8 Background context of the guideline on Developing and Sustaining Nursing Leadership 12 Purpose and scope of this document 13 How to use this document 15 Conceptual (...) Appendix C: RNAO Framework and LEADS Framework Comparison 123 Appendix D: Process for systematic review of the literature on developing and sustaining Nursing leadership completed by the Joanna Briggs Institute 125 Appendix E: Glossary of terms 129 Appendix F: Guideline development process 133 Appendix G: Description of the toolkit 135 Appendix H: Article Review Process Flow Diagram 137 BACKGROUND RECOMMENDATIONS APPENDICES REF.BEST PRACTICE GUIDELINES WWW.RNAO.ORG 4 Developing and Sustaining Nursing

2013 Registered Nurses' Association of Ontario

17. CPG for Diabetes Mellitus Type 1

for Health Technology Assessment from the Basque Country - Osteba, in the framework of cooperation envisaged in the Quality Plan for the National Health Service of the Ministry of Health and Social Policy. This guide should include: Working Group of the Clinical Practice Guideline on Diabetes mellitus type 1. Clinical Practice Guidelines for Diabetes mellitus type 1. Quality Plan for the National Health Service of the Ministry of Health and Social Policy. Agency for Health Technology Assessment from

2012 GuiaSalud

18. CPG for the Prevention and Treatment of Suicidal Behaviour

NIPO MSPSI: 860-11-161-2 Legal deposit: C. 1.650-2012 Lay-out: Tórculo Artes Grá? cas, SA. It has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. "This CPG was ? nanced by the agreement signed by the Carlos III Health Institute, an autonomous body of the Ministry of Science and Research, and the Galician Agency for Health T echnology Assessment(AVALIA-T) within the framework of cooperation provided for in the Ministry of Health National Health

2012 GuiaSalud

19. Cardiovascular Risk in Asymptomatic Adults: Guideline For Assessment of

e61 2.3. Lipoprotein and Apolipoprotein Assessments e61 2.3.1. Recommendation for Lipoprotein and Apolipoprotein Assessments e61 2.3.2. Assessment of Lipoprotein Concentrations, Other Lipoprotein Parameters, and Modi?ed Lipids e61 2.3.3. Risk Prediction Relationships Beyond Standard Risk Factors e62 2.3.4. Usefulness in Motivating Patients or Guiding Therapy e62 2.3.5. Evidence for Improved Net Health Outcomes e62 2.4. Other Circulating Blood Markers and Associated Conditions e62 2.4.1 (...) IN MOTIVATING PATIENTS OR GUIDING THERAPY e71 2.5.3.5. EVIDENCE FOR IMPROVED NET HEALTH OUTCOMES e71 2.5.4. Brachial/Peripheral Flow-Mediated Dilation e71 2.5.4.1. RECOMMENDATION FOR BRACHIAL/PERIPHERAL FLOW-MEDIATED DILATION e71 2.5.4.2. GENERAL DESCRIPTION e71 2.5.4.3. ASSOCIATION WITH INCREASED RISK AND INCREMENTAL PREDICTION e71 2.5.4.4. USEFULNESS IN MOTIVATING PATIENTS OR GUIDING THERAPY e72 2.5.4.5. CHANGES IN PATIENT OUTCOMES e72 2.5.5. Pulse Wave Velocity and Other Arterial Abnormalities: Measures

2010 American College of Cardiology

20. CPG on the comprehensive care of people with Alzheimer's Disease and other Dementias

Copyright deposit. B. 34.475-2011 It has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. This CPG has been funded through the agreement signed by the Instituto de Salud Carlos II, an independent body of the Ministry of Science and Innovation, and the Agencia d’Informació, Avaluació I Qualitat en Salut (AIAQS, previously the Agència d’Avaluació de Tecnologia i Recerca Mèdiques, AATRM) of Catalonia, within the collaboration framework provided (...) with Alzheimer’s disease and other dementias, by association of patients and relatives, scienti? c societies and other entities involved in the care of these people. CARMEN MOYA GARCÍA General Director of the Quality Agency of the SNS It has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. CLINICAL PRACTICE GUIDELINE ON THE COMPREHENSIVE CARE OF PEOPLE WITH ALZHEIMER’S DISEASE AND OTHER DEMENTIAS 9 Authors and collaborations CPG Development Group

2010 GuiaSalud

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>